NL8403181A - 4-chloorfuro(3,4-c)pyridinederivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die hen bevatten. - Google Patents
4-chloorfuro(3,4-c)pyridinederivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die hen bevatten. Download PDFInfo
- Publication number
- NL8403181A NL8403181A NL8403181A NL8403181A NL8403181A NL 8403181 A NL8403181 A NL 8403181A NL 8403181 A NL8403181 A NL 8403181A NL 8403181 A NL8403181 A NL 8403181A NL 8403181 A NL8403181 A NL 8403181A
- Authority
- NL
- Netherlands
- Prior art keywords
- dihydro
- pyridine
- furo
- hydroxy
- methyl
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 238000000034 method Methods 0.000 title description 13
- REIGINRVLDUJCQ-UHFFFAOYSA-N 4-chlorofuro[3,4-c]pyridine Chemical class ClC1=NC=CC2=COC=C12 REIGINRVLDUJCQ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- GFEZPGADIMGWOH-UHFFFAOYSA-N 6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical class CC1=NC=C2COCC2=C1O GFEZPGADIMGWOH-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000047 product Substances 0.000 description 20
- 238000000921 elemental analysis Methods 0.000 description 19
- 238000002844 melting Methods 0.000 description 19
- 230000008018 melting Effects 0.000 description 19
- -1 N-pyrrolidinyl group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 description 2
- KNPYGVJKIDHJHS-UHFFFAOYSA-N 4-chloro-6-methylfuro[3,4-c]pyridin-7-ol Chemical compound ClC1=NC(=C(C=2C1=COC=2)O)C KNPYGVJKIDHJHS-UHFFFAOYSA-N 0.000 description 2
- NZOCLVWZHBNOKT-UHFFFAOYSA-N 6-methylfuro[3,4-c]pyridin-7-ol Chemical compound OC1=C(C)N=CC2=COC=C21 NZOCLVWZHBNOKT-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GJVNMIQVQXYJCP-UHFFFAOYSA-N furo[3,4-c]pyridine Chemical class C1=NC=CC2=[C]OC=C21 GJVNMIQVQXYJCP-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 description 2
- 229960000356 tienilic acid Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- KRFFDJKRFIRFEH-UHFFFAOYSA-N 3,3,6-trimethyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound CC1=NC=C2C(C)(C)OCC2=C1O KRFFDJKRFIRFEH-UHFFFAOYSA-N 0.000 description 1
- WPRNMWVODLENAP-UHFFFAOYSA-N 3,6-dimethyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound C1=NC(C)=C(O)C2=C1C(C)OC2 WPRNMWVODLENAP-UHFFFAOYSA-N 0.000 description 1
- VFROHEFJKCMRAI-UHFFFAOYSA-N 3,6-dimethyl-3-phenyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound OC=1C(C)=NC=C2C=1COC2(C)C1=CC=CC=C1 VFROHEFJKCMRAI-UHFFFAOYSA-N 0.000 description 1
- JJGRSVSRPHZQGZ-UHFFFAOYSA-N 3-(2,3-dichlorophenyl)-6-methyl-3-phenyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound OC=1C(C)=NC=C2C=1COC2(C=1C(=C(Cl)C=CC=1)Cl)C1=CC=CC=C1 JJGRSVSRPHZQGZ-UHFFFAOYSA-N 0.000 description 1
- UHEZOMQCEAKBIE-UHFFFAOYSA-N 3-(4-methoxyphenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound C1=CC(OC)=CC=C1C1C(C=NC(C)=C2O)=C2CO1 UHEZOMQCEAKBIE-UHFFFAOYSA-N 0.000 description 1
- FXNRMPYJNRGEAG-UHFFFAOYSA-N 4-chloro-3,3,6-trimethyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound CC1=NC(Cl)=C2C(C)(C)OCC2=C1O FXNRMPYJNRGEAG-UHFFFAOYSA-N 0.000 description 1
- CZOLAEVRQAMQJD-UHFFFAOYSA-N 4-chloro-3,6-dimethyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound ClC1=NC(C)=C(O)C2=C1C(C)OC2 CZOLAEVRQAMQJD-UHFFFAOYSA-N 0.000 description 1
- BJJGWGOGOMEECW-UHFFFAOYSA-N 4-chloro-3-(2,3-dichlorophenyl)-6-methyl-3-phenyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound OC=1C(C)=NC(Cl)=C2C=1COC2(C=1C(=C(Cl)C=CC=1)Cl)C1=CC=CC=C1 BJJGWGOGOMEECW-UHFFFAOYSA-N 0.000 description 1
- YYSDEJFOFNQOAW-UHFFFAOYSA-N 4-chloro-3-(4-methoxyphenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound COC1=CC=C(C=C1)C1OCC2=C1C(=NC(=C2O)C)Cl YYSDEJFOFNQOAW-UHFFFAOYSA-N 0.000 description 1
- SCVKXHUUQDXCGX-UHFFFAOYSA-N 4-chloro-6-methyl-3,3-diphenyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound OC=1C(C)=NC(Cl)=C2C=1COC2(C=1C=CC=CC=1)C1=CC=CC=C1 SCVKXHUUQDXCGX-UHFFFAOYSA-N 0.000 description 1
- JFRALSHFDCJIIA-UHFFFAOYSA-N 4-chloro-6-methyl-3-(2-phenylethyl)-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound O1CC2=C(O)C(C)=NC(Cl)=C2C1CCC1=CC=CC=C1 JFRALSHFDCJIIA-UHFFFAOYSA-N 0.000 description 1
- ZUPIHGKUZAAWLZ-UHFFFAOYSA-N 4-chloro-6-methyl-3-phenylfuro[3,4-c]pyridin-7-ol Chemical compound C1(=CC=CC=C1)C=1OC=C2C=1C(=NC(=C2O)C)Cl ZUPIHGKUZAAWLZ-UHFFFAOYSA-N 0.000 description 1
- IZUQTLUIHJUBRX-UHFFFAOYSA-N 4-chloro-6-methyl-3-propyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound ClC1=NC(C)=C(O)C2=C1C(CCC)OC2 IZUQTLUIHJUBRX-UHFFFAOYSA-N 0.000 description 1
- HBLJSMREXQKFNU-UHFFFAOYSA-N 6-methyl-3,3-diphenyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound OC=1C(C)=NC=C2C=1COC2(C=1C=CC=CC=1)C1=CC=CC=C1 HBLJSMREXQKFNU-UHFFFAOYSA-N 0.000 description 1
- AXZNOBIHGUZGPG-UHFFFAOYSA-N 6-methyl-3-(2-phenylethyl)-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound O1CC2=C(O)C(C)=NC=C2C1CCC1=CC=CC=C1 AXZNOBIHGUZGPG-UHFFFAOYSA-N 0.000 description 1
- JYFOHPOYHZRXBO-UHFFFAOYSA-N 6-methyl-3-(4-methylphenyl)-3-pentyl-1h-furo[3,4-c]pyridin-7-ol Chemical compound O1CC(C(=C(C)N=C2)O)=C2C1(CCCCC)C1=CC=C(C)C=C1 JYFOHPOYHZRXBO-UHFFFAOYSA-N 0.000 description 1
- AWSNANLRLHTJCZ-UHFFFAOYSA-N 6-methyl-3-phenyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound O1CC2=C(O)C(C)=NC=C2C1C1=CC=CC=C1 AWSNANLRLHTJCZ-UHFFFAOYSA-N 0.000 description 1
- VABUPDWURAFFTL-UHFFFAOYSA-N 6-methyl-3-propyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound C1=NC(C)=C(O)C2=C1C(CCC)OC2 VABUPDWURAFFTL-UHFFFAOYSA-N 0.000 description 1
- YBKNUCZIQPYKAO-UHFFFAOYSA-N CC1=C(C2=C(OC=C2C(=N1)Cl)C3COC=C3)O Chemical compound CC1=C(C2=C(OC=C2C(=N1)Cl)C3COC=C3)O YBKNUCZIQPYKAO-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- CEALXSHFPPCRNM-UHFFFAOYSA-L disodium;carboxylato carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OC([O-])=O CEALXSHFPPCRNM-UHFFFAOYSA-L 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB838327817A GB8327817D0 (en) | 1983-10-18 | 1983-10-18 | 4-halo-furo-(3 4-c)-pyridine derivatives |
GB8327817 | 1983-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL8403181A true NL8403181A (nl) | 1985-05-17 |
Family
ID=10550364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL8403181A NL8403181A (nl) | 1983-10-18 | 1984-10-18 | 4-chloorfuro(3,4-c)pyridinederivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die hen bevatten. |
Country Status (24)
Country | Link |
---|---|
US (1) | US4585776A (en, 2012) |
JP (1) | JPS60104090A (en, 2012) |
AT (1) | AT391699B (en, 2012) |
BE (1) | BE900780A (en, 2012) |
CA (1) | CA1257270A (en, 2012) |
CH (1) | CH662118A5 (en, 2012) |
DE (1) | DE3438244A1 (en, 2012) |
DK (1) | DK158003C (en, 2012) |
DZ (1) | DZ687A1 (en, 2012) |
ES (1) | ES536814A0 (en, 2012) |
FI (1) | FI80036C (en, 2012) |
FR (2) | FR2553417B1 (en, 2012) |
GB (2) | GB8327817D0 (en, 2012) |
HK (1) | HK54787A (en, 2012) |
IE (1) | IE58041B1 (en, 2012) |
IT (1) | IT1176986B (en, 2012) |
LU (1) | LU85583A1 (en, 2012) |
MA (1) | MA20251A1 (en, 2012) |
NL (1) | NL8403181A (en, 2012) |
OA (1) | OA07840A (en, 2012) |
PT (2) | PT79369B (en, 2012) |
SE (1) | SE459093B (en, 2012) |
SG (1) | SG25387G (en, 2012) |
ZA (1) | ZA847961B (en, 2012) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808001D0 (en) * | 1988-04-06 | 1988-05-05 | Scras | Stereospecific preparative process for furol(3,4-c)pyridine derivatives |
GB8907480D0 (en) * | 1989-04-03 | 1989-05-17 | Scaras Societe De Conseils De | Separation of insomers of furo(3,4-c)pyridine derivatives |
GB8917168D0 (en) * | 1989-07-27 | 1989-09-13 | Scras | Asymmetric synthesis of furo(3,4-c)pyridine derivatives |
US5130252A (en) * | 1990-05-14 | 1992-07-14 | Synthetech, Inc. | Resolution of furopyridine enantiomers and synthetic precursors thereof |
US6865862B2 (en) * | 2000-11-20 | 2005-03-15 | C.G. Bretting Mfg. Co., Inc. | Log bander apparatus and method |
GB0221494D0 (en) * | 2002-09-16 | 2002-10-23 | Generics Uk Ltd | Novel processes for the preparation of 1.3-dihydro-6-methylfuro (3,4-c) pyndin derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5621578B2 (en, 2012) * | 1973-06-02 | 1981-05-20 | ||
ZA786269B (en) * | 1977-11-25 | 1979-10-31 | Scras | New pyridine derivative,its preparation and use |
GB2008582B (en) * | 1977-11-25 | 1982-04-28 | Scras | Pyridine derivative |
IN156817B (en, 2012) * | 1981-02-10 | 1985-11-09 | Scras |
-
1983
- 1983-10-18 GB GB838327817A patent/GB8327817D0/en active Pending
-
1984
- 1984-10-09 BE BE0/213802A patent/BE900780A/fr not_active IP Right Cessation
- 1984-10-10 CH CH4863/84A patent/CH662118A5/fr not_active IP Right Cessation
- 1984-10-10 LU LU85583A patent/LU85583A1/fr unknown
- 1984-10-11 GB GB08425704A patent/GB2148292B/en not_active Expired
- 1984-10-11 ZA ZA847961A patent/ZA847961B/xx unknown
- 1984-10-12 SE SE8405118A patent/SE459093B/sv not_active IP Right Cessation
- 1984-10-13 DZ DZ847301A patent/DZ687A1/fr active
- 1984-10-15 MA MA20475A patent/MA20251A1/fr unknown
- 1984-10-15 FI FI844034A patent/FI80036C/fi not_active IP Right Cessation
- 1984-10-16 US US06/661,376 patent/US4585776A/en not_active Expired - Lifetime
- 1984-10-17 JP JP59216483A patent/JPS60104090A/ja active Granted
- 1984-10-17 IE IE266384A patent/IE58041B1/en not_active IP Right Cessation
- 1984-10-17 DK DK495984A patent/DK158003C/da not_active IP Right Cessation
- 1984-10-17 PT PT79369A patent/PT79369B/pt not_active IP Right Cessation
- 1984-10-17 ES ES536814A patent/ES536814A0/es active Granted
- 1984-10-17 IT IT23176/84A patent/IT1176986B/it active
- 1984-10-18 OA OA58417A patent/OA07840A/xx unknown
- 1984-10-18 DE DE19843438244 patent/DE3438244A1/de active Granted
- 1984-10-18 AT AT0332984A patent/AT391699B/de not_active IP Right Cessation
- 1984-10-18 FR FR8415948A patent/FR2553417B1/fr not_active Expired
- 1984-10-18 FR FR8415947A patent/FR2553286B1/fr not_active Expired
- 1984-10-18 NL NL8403181A patent/NL8403181A/nl not_active Application Discontinuation
- 1984-10-18 CA CA000465804A patent/CA1257270A/en not_active Expired
- 1984-11-16 PT PT79512A patent/PT79512B/pt not_active IP Right Cessation
-
1987
- 1987-03-12 SG SG253/87A patent/SG25387G/en unknown
- 1987-07-23 HK HK547/87A patent/HK54787A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3679930A1 (en) | Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity | |
KR900003499B1 (ko) | 퀴놀린계 화합물, 그의 제조방법 및 그 화합물을 약효성분으로 함유하는 항암제 | |
NL8403181A (nl) | 4-chloorfuro(3,4-c)pyridinederivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die hen bevatten. | |
EP1560818A1 (en) | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use | |
WO1993016698A1 (en) | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES | |
CN101863901B (zh) | 2-(取代苯基)-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5(4H)-基)-N-取代-乙酰胺、其制备方法和用途 | |
JPS6222771A (ja) | 5−置換−6−アミノピリミジン誘導体、組成物および使用 | |
CN110857304B (zh) | Trk抑制剂、其制备方法和用途 | |
CN107827837B (zh) | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 | |
CZ321095A3 (en) | Heterocyclic compounds | |
JPH10507446A (ja) | ビス−2−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途 | |
JPS63135378A (ja) | ブチロラクトン誘導体、その製造方法およびその用途 | |
Kametani et al. | Studies on the synthesis of chemotherapeutics. 12. Synthesis and antitumor activity of N-phthalidyl-5-fluorouracil derivatives | |
EP0058134B1 (en) | Novel bis- and poly-disulfides having immunostimulant activity | |
CN101845052B (zh) | 一类含氮杂环的噻吩并吡啶酮衍生物、其制备方法和用途 | |
US6107304A (en) | Thieno[2,3-b]pyrazolo[3,4-d]pyridine-3-ones to enhance erythropoiesis | |
CZ380596A3 (en) | Salts of 2-(2,6-dichlorophenyl)amino)phenylacetoxyacetic acid with cations of organic bases, process of their preparation, pharmaceutical compositions containing thereof and their use | |
CN101805355B (zh) | 一类噻吩并吡啶酮衍生物、其制备方法和用途 | |
KR940001777B1 (ko) | N-메톡시페닐에틸-n'-이미다졸릴페닐아미딘 유도체 및 그의 제조방법 | |
RU2068415C1 (ru) | 5,7-диокси-2-метил-8-/4-(3-окси-1-(1-пропил)пиперидинил/-4н-1-бензопиран-4-он или его стереоизомеры или фармакологически приемлемые кислотно-аддитивные соли и способ их получения | |
EP0821961A1 (en) | Neovascularization inhibitor | |
ZA200508519B (en) | 4-(4-trans-hydroxycyclohexyl) amino-2-phenyl-7H-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms | |
EP0061434A1 (en) | Derivatives of 2-amino-5-(o-sulphamidophenyl)-1,3,4-thiadiazole as antiviral agents and a process for the preparation thereof | |
SE461394B (sv) | 6-aminometyl-furo-(3,4-c)-pyridinderivat, deras framstaellning och farmaceutiska kompositioner innehaallande dem | |
CN102417514B (zh) | 吡啶衍生物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BA | A request for search or an international-type search has been filed | ||
BB | A search report has been drawn up | ||
BC | A request for examination has been filed | ||
BV | The patent application has lapsed |